Curative Biotechnology Inc (CUBT)

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel...  immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.  और पढ़ें

• President & Executive Chairman

  Mr. Paul M. Michaels

• CEO, CFO, Principal Accounting Officer & General Counsel

  Mr. I. Richard Garr Esq., J.D.

• हेडक्वार्टर्स

  Palm Beach Gardens, FL

• वेबसाइट

  https://curativebiotech.com